title: GABAergic regulation of tuberoinfundibular dopaminergic neurons in the male rat.
abstract: The purpose of the present study was to examine the effects of gamma-aminobutyric acid (GABA)A and GABAB receptor blockade and activation on the activity of tuberoinfundibular dopaminergic (TIDA) neurons in male rats. The activity of TIDA neurons was estimated by measuring the concentration of the primary dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the median eminence. Administration of the GABAA receptor antagonist SR 95531 increased DOPAC concentrations in the median eminence, and decreased plasma concentrations of prolactin, in a dose- and time-related manner. Administration of the GABAA receptor agonist isoguvacine had no effect per se on DOPAC concentrations in the median eminence, but produced a delayed decrease in plasma prolactin concentrations. Isoguvacine pre-treatment prevented the increase in DOPAC concentrations in the median eminence produced by SR 95531. In contrast, administration of the GABAB receptor agonist baclofen decreased DOPAC concentrations in the median eminence, and increased plasma prolactin concentrations in a dose-dependent manner. Administration of the GABAB receptor antagonist 2-hydroxysaclofen had no effect on TIDA neurons per se, but blocked baclofen-induced decreases in DOPAC concentrations in the median eminence and increases in plasma prolactin concentrations. These results indicate that while activation of GABAB receptors inhibits TIDA neurons, these neurons are tonically inhibited by endogenous GABA acting at GABAA but not GABAB receptors.
authors: Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824.
authors: E J
authors: EJ
authors: Wagner
authors: J L
authors: JL
authors: Goudreau
authors: K E
authors: KE
authors: Moore
authors: K J
authors: KJ
authors: Lookingland
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001418:Baclofen / Q000031:analogs & derivatives / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D007031:Hypothalamus / Q000166:cytology / Q000502:physiology*; D007539:Isonicotinic Acids / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000502:physiology*; D009994:Osmolar Concentration; D011388:Prolactin / Q000097:blood; D011724:Pyridazines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000139:chemically induced; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
chemical_list: D018755:GABA Agonists; D018756:GABA Antagonists; D007539:Isonicotinic Acids; D011724:Pyridazines; D015102:3,4-Dihydroxyphenylacetic Acid; D005680:gamma-Aminobutyric Acid; D011388:Prolactin; C049853:gabazine; D001418:Baclofen; D004298:Dopamine; C057491:2-hydroxysaclofen; C015300:isoguvacine